MS RESEARCH AUSTRALIA TRIALS
Additional medical conditions can worsen MS symptoms and are an important target for intervention to improve quality of life for people with MS
Mayzent (siponimod) the first MS medication approved for secondary progessive MS in Australia, has been listed on the Pharmaceutical Benefits Scheme (PBS).
A panel of international experts have convened to develop new ways to measure disease progression in progressive MS, a major hurdle for clinical trials.
Two MS Research Australia funded research groups are investigating the role of messenger molecules and uncovering how genes increase the risk of ms.